Krufton (Nilotinib Hydrochloride Dihydrate)

Nilotinib blocks the BCR‑ABL tyrosine kinase by occupying its ATP‑binding pocket, which stops downstream signaling that promotes uncontrolled growth of malignant blood cells. This inhibition restores normal cellular regulation and leads to apoptosis of the leukemic clone.

The dose of Krufton is individualized by the treating physician based on the patient’s disease status, prior therapy, renal and hepatic function, and potential drug interactions. Only a qualified prescriber should set the dosing regimen.

Nilotinib is classified as pregnancy category D, indicating evidence of risk to the fetus. It is contraindicated in pregnancy and not recommended while breastfeeding because it can be excreted in milk and may harm the infant.

To request Krufton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Krufton (nilotinib) is a second‑generation BCR‑ABL inhibitor, offering higher potency and activity against many imatinib‑resistant mutations. Compared with first‑generation agents, it often achieves faster and deeper molecular responses, but it also carries a distinct safety profile that requires cardiac and metabolic monitoring.

Krufton tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Krufton is taken orally, usually as a whole tablet swallowed with a moderate‑fat meal to improve absorption. Patients should follow the prescriber’s instructions regarding timing, food intake, and any required dose adjustments.

The most critical adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe liver toxicity, and pancreatitis. Regular ECG monitoring, liver function tests, and prompt reporting of symptoms such as chest pain, jaundice or severe abdominal pain are essential.

Krufton is contraindicated in patients with a known hypersensitivity to nilotinib or any component of the formulation, in pregnant or nursing women, and in individuals with a history of significant QT prolongation or uncontrolled cardiac disease unless the benefits outweigh the risks.